skip to main content

Phytochemicals as a potential inhibitor of Spike Protein of SARS-CoV-2 Omicron Variant

Tuti Ratnasari  -  Department of Medicine, Faculty of Medicine, Diponegoro University, Indonesia, Indonesia
*Faizah Fulyani orcid  -  Department of Medical Biology and Biochemistry, Faculty of Medicine, Diponegoro University, Semarang, Indonesia, Indonesia
Endang Mahati  -  Department of Pharmacology Faculty of Medicine, Diponegoro University, Semarang, Indonesia, Indonesia

Citation Format:
Abstract

Background: More than 50 mutations have been found in Omicron SARS-CoV-2. Most Omicron mutations are located in the spike protein, which plays a pivotal role in virus infection. The mutated spike protein in the Omicron variant increases virus transmissibility and potentially threatens the effectiveness of COVID-19 vaccines and antibody therapies. Herbal plants, such as Indian Ayurveda, African herbal plants, and Traditional Chinese Medicines (TCM), have been studied as SARS-CoV-2 potential therapy in several countries.

Objective: This review explores potential phytochemical herbals that target spike protein omicron based on the available molecular docking studies.

Methods: We collected research articles on the molecular docking of phytochemicals that target spike protein omicron. Combination of several keywords: in silico OR molecular docking AND spike omicron, were used as input for Google search. Out of 83 articles from Google search, eight articles matched the inclusion criteria and were selected in this review.

Result: Protodioscin from Carica papaya and Landomycin A from Aloe vera are the most potential phytochemical inhibitors against spike protein with the free binding energy of -10.77 kcal/mol and -10kcal/mol, respectively.  

Note: This article has supplementary file(s).

Fulltext View|Download |  Turnitin result
Turnitin Phytochemicals as a potential inhibitor of Spike Protein
Subject
Type Turnitin result
  Download (3MB)    Indexing metadata
Keywords: in silico, molecular docking, herbals phytochemical, spike glycoprotein, omicron

Article Metrics:

  1. References
  2. C. Lai, T. Shih, W. Ko, H. Tang, and P. Hsueh, “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges,” Int. J. Antimicrob. Agents, vol. 55, no. January 2020
  3. World Health Organization, “WHO Coronavirus Disease (COVID-19), Overview Data Coronavirus Disease (COVID-19).” p. 1, 2022. [Online]. Available: https://covid19.who.int/?mapFilter=cases
  4. E. Chekol Abebe et al., "Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection," Infect. Drug Resist., vol. 15, no. April, pp. 1871–1887, 2022, doi: 10.2147/IDR.S360103
  5. M. Young, H. Crook, J. Scott, and P. Edison, "Covid-19: virology, variants, and vaccines," BMJ Med., vol. 1, no. 1, p. e000040, 2022, doi: 10.1136/bmjmed-2021-000040
  6. W. Dejnirattisai, "SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses," Cell, vol. 185, no. 3, pp. 467-484.e15, 2022, doi: 10.1016/j.cell.2021.12.046
  7. W. Jassat et al., "Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study," Lancet Glob. Heal., vol. 10, no. 7, pp. e961–e969, 2022, doi: 10.1016/S2214-109X(22)00114-0
  8. D. Gupta, P. Sharma, M. Singh, M. Kumar, and A. S. E. Punit, "Structural and functional insights into the spike protein mutations of emerging SARS ‑ CoV ‑ 2 variants," Cell. Mol. Life Sci., vol. 78, no. 24, pp. 7967–7989, 2021, doi: 10.1007/s00018-021-04008-0
  9. G. M. H. M. I. H. Naqvia, Ahmad Abu Turab Kisa Fatima, Taj Mohammad, Urooj Fatima, Indrakant K Singh, Archana Singh, Shaikh Muhammad Atif, Gururao Hariprasadg, "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach," Mol. Basis Dis., vol. 20:58, no. 10, p. 165878, 2020, doi: 10.1016/j.bbadis.2020.165878
  10. Y. Gandhi, S. K. Mishra, H. Rawat, J. Grewal, and R. Kumar, "Phytomedicines explored under in vitro and in silico studies against coronavirus: An opportunity to develop traditional medicines," South African J. Bot., vol. 151, no. January, pp. 451–483, 2020
  11. P. F. N. Souza et al., "The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape," Int. J. Biol. Macromol., vol. 208, no. March, pp. 105–125, 2022, doi: 10.1016/j.ijbiomac.2022.03.058
  12. C. rong Wu, W. chao Yin, Y. Jiang, and H. E. Xu, "Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19," Acta Pharmacol. Sin., no. October 2021, pp. 1–13, 2022, doi: 10.1038/s41401-021-00851-w
  13. A. Tuekprakhon et al., "Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum," Cell, pp. 2422–2433, 2022, doi: 10.1016/j.cell.2022.06.005
  14. G. S. Suresh Kumar, Kalimuthu Karuppanan, "Omicron (BA.1) and sub‐variants (BA.1.1, BA.2, and BA.3) of SARS‐CoV‐2 spike infectivity and pathogenicity: A comparative sequence and structural‐based computational assessment." 2022
  15. T. Z. Gabriele Cerutti, Yicheng Guo, "Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite Graphical," Cell Press, no. January, pp. 819–833, 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254017/pdf/main.pdf
  16. X. Chi et al., "A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2," Science (80-. )., vol. 655, no. August, pp. 650–655, 2020
  17. X. An, Y. Zhang, L. Duan, D. Jin, and S. Zhao, "Biomedicine & Pharmacotherapy The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19," Biomed. Pharmacother., vol. 137, no. December 2020, p. 111267, 2021, doi: 10.1016/j.biopha.2021.111267
  18. J. et al Roshni, "Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529," J. Infect. Public Health, vol. 15, no. January, pp. 662–669, 2020
  19. S. Forli, R. Huey, M. E. Pique, M. Sanner, D. S. Goodsell, and J. Arthur, "Computational protein-ligand docking and virtual drug screening with the AutoDock suite," Nat Protoc, vol. 11, no. 5, pp. 905–919, 2016, doi: 10.1038/nprot.2016.051.Computational
  20. Oleg Trott and Arthur J. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading," J Comput Chem, vol. 31, no. 2, pp. 455–461, 2011, doi: 10.1002/jcc.21334.AutoDock
  21. National Library of Medicine, "Chemistry." p. https://pubchem.ncbi.nlm.nih.gov/, 2023. [Online]. Available:
  22. X. Yang, B. Fu, and B. Yu, "Total Synthesis of Landomycin A, a Potent Antitumor Angucycline Antibiotic," pp. 12433–12435, 2011
  23. A. Terenzi et al., "Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism," pp. 1–13, 2021, doi: 10.1038/s42004-021-00600-4
  24. B. J. Kepel and M. J. Kalalo, "Employing an in-silico approach in the evaluation of Aloe vera metabolites as inhibitors of Omicron RBD and the ROS-dependent cellular signaling processes," J. Appl. Pharm. Sci. Vol., vol. 13, no. 03, pp. 114–131, 2023, doi: 10.7324/JAPS.2023.130304
  25. M. M. Espindola KMM, Ferreira RG, Narvaez LEM, Silva Rosario ACR, da Silva AHM, Silva AGB, Vieira APO, "Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma," vol. 9, no. June, pp. 3–5, 2019, doi: 10.3389/fonc.2019.00541
  26. T. S. and C. C. Bharathi M., Sivamaruthi B., Trimer, Kesika P, "In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron," Mar. Drugs, no. November 2021, pp. 1–18, 2022
  27. H. S. Tuli, P. Rath, A. Chauhan, S. Ramniwas, and K. Vashishth, "Phloretin , as a Potent Anticancer Compound : From Chemistry," pp. 1–15, 2022
  28. J. Stabrauskiene, D. M. Kopustinskiene, R. Lazauskas, and J. Bernatoniene, "Naringin and Naringenin : Their Mechanisms of Action and the Potential Anticancer Activities," Biomedicine, pp. 1–16, 2022
  29. H. Tutunchi, F. Naeini, and M. J. Hosseinzadeh-attar, "Naringenin , a flavanone with antiviral and anti-inflammatory effects : A promising treatment strategy against COVID-19," no. April, pp. 3137–3147, 2020, doi: 10.1002/ptr.6781
  30. S. Khaerunnisa, H. Kurniawan, R. Awaluddin, and S. Suhartati, "Potential Inhibitor of COVID-19 Main Protease ( M pro ) from Several Medicinal Plant Compounds by Molecular Docking Study," Preprints, no. March, pp. 1–14, 2020, doi: 10.20944/preprints202003.0226.v1
  31. W. Liu et al., "Citrus fruits are rich in flavonoids for immunoregulation and potential targeting," Nat. Products Bioprospect., vol. 4, 2022, doi: 10.1007/s13659-022-00325-4
  32. W. P. R. T. Perera et al., "Review Article Antiviral Potential of Selected Medicinal Herbs and Their Isolated Natural Products," vol. 2021, 2021
  33. O. A. Adeleye, O. A. Bamiro, L. G. Bakre, and F. O. Odeleye, "Medicinal Plants with Potential Inhibitory Bioactive Compounds against Coronaviruses," Tabriz Univ. Med. Sci., vol. 12, no. 1, pp. 7–16, 2022, doi: 10.34172/apb.2022.003
  34. A. C. Pushkaran, P. N. En, and S. V Nair, "Structure-based bioactive phytochemical design from Ayurvedic formulations towards Spike and M pro druggable targets of SARS-CoV-2"
  35. A. C. Pushkaran, P. N. En, A. R. Melge, R. Puthiyedath, and C. G. Mohan, "A phytochemical-based medication search for the SARS-CoV-2 infection by molecular docking models towards spike glycoproteins and main," RSC Adv., pp. 12003–12014, 2021, doi: 10.1039/d0ra10458b
  36. P. P. Carriere, N. Kapur, H. Mir, A. B. Ward, and S. Singh, "Cinnamtannin B-1 inhibits cell survival molecules and induces apoptosis in colon cancer," Int. J. Oncol., vol. 53, pp. 1442–1454, 2018, doi: 10.3892/ijo.2018.4489
  37. R. Vinyagam, P. Kumar, K. E. Lee, and B. Xu, "Biological and Functional Properties of Wedelolactone in Human Chronic Diseases Biological and Functional Properties of Wedelolactone in Human Chronic Diseases," no. November, pp. 0–15, 2020, doi: 10.32604/phyton.2020.013388
  38. S. Katuwal et al., "In Silico Study of Coumarins : Wedelolactone as a Potential Inhibitor of the Spike Protein of the SARS-CoV-2 Variants," Hindawi, vol. 2023, 2023
  39. S. Bakrim et al., "Natural Sources and Pharmacological Properties of Pinosylvin," pp. 1–23, 2022
  40. P. Bansal, H. S. Tuli, V. Sharma, R. K. Mohapatra, K. Dhama, and A. K. Sharma, "Journal of Experimental Biology and Agricultural Sciences Targeting Omicron ( B . 1 . 1 . 529 ) SARS CoV-2 spike protein with selected phytochemicals : an in-silico approach for identification of potential drug," J. Exp. Biol. Agric. Sci., vol. 10, no. 2320, pp. 396–404, 2022
  41. A. Swaroop, A. Maheshwari, N. Verma, K. Tiwari, and P. Kumar, "A novel protodioscin-enriched fenugreek seed extract ( Trigonella foenum-graecum , family Fabaceae ) improves free testosterone level and sperm profile in healthy volunteers," Funct. Foods Heal. Dis. 2017, vol. 7, no. 4, pp. 235–245, 2017
  42. L. Chen et al., "Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer," Hindawi, 2018
  43. M. Shukri, A. Shukor, N. Enterprise, and Y. Shukor, "Molecular Docking and Dynamics Studies Show Phytochemicals from Papaya leaves Extracts as Potent Inhibitors of SARS-CoV-2 Proteins Targets and TNF- alpha and Alpha Thrombin : A Poten ... Molecular Docking and Dynamics Studies Show Phytochemicals from Papaya leaves Extracts as Potent Inhibitors of SARS – CoV – 2 Proteins Targets and TNF – alpha and Alpha Thrombin : A Potential Holistic Weapon in Combating COVID – 19," no. April, 2022, doi: 10.13140/RG.2.2.27777.53602
  44. Y. Song et al., "Maysin and Its Flavonoid Derivative from Centipedegrass Attenuates Amyloid Plaques by Inducting Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg ( APPswe , PS1dE9 ) Alzheimer' s Mouse Model," vol. 2, pp. 1–20, 2017, doi: 10.1371/journal.pone.0169509
  45. Desie Dwi Wisudanti, "Therapeutic Application Of Geraniin From Rambutan (Nephelium Lappaceum) Peel Extract As Antihyperglycemic Through Its Antioxcidant Activity In Type 2 Diabetes Mellitus," 2016
  46. H. M. Sharanya CS., Abhitaj J., Sabu A., "COVID-19 Omicron variant-inhibitory in silico evidence for phytocompounds of an ancient Ayurvedic formulation," Chemrxiv, 2022
  47. J. Yu, M. M. Xuhong Tiang, C. Zhai, and J. Xiaodong, "A computer simulation-based study on the intervention of active ingredients of Mongolian medicine into the S-protein of SARS-CoV-2-associated variant Omicron Author information"
  48. J. O. Aribisala, C. E. Aruwa, T. O. Uthman, I. O. Nurain, K. Idowu, and S. Sabiu, "Cheminformatics Bioprospection of Broad Spectrum Plant Secondary Metabolites Targeting the Spike Proteins of Omicron Variant and Wild-Type SARS-CoV-2," Metabolites, 2022
  49. Y. S. Kim, H. Chung, S. G. Noh, B. Lee, H. Y. Chung, and J. Choi, "Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor," 2021

Last update:

No citation recorded.

Last update:

No citation recorded.